Tearsheet

Venus Concept (VERO)

Market Price (12/18/2025): $1.64 | Market Cap: $3.0 Mil
Sector: Health Care | Industry: Life Sciences Tools & Services

Venus Concept (VERO)

Market Price (12/18/2025): $1.64
Market Cap: $3.0 Mil
Sector: Health Care
Industry: Life Sciences Tools & Services

Investment Highlights Why It Matters Which of these 2 stories sounds closer for this stock?

1. Generates cash flow

The stock generated 4% or more of the share price (called cash flow yield), and shows moderate 10-15% or more growth.

2. Riding a trend

Think Tesla during the pandemic of 2020 when EVs were riding a cultural high, or Nvidia in the current AI boom, or even Figma. These companies don’t have enough yield, or, enough growth, or both - however - they are riding a trend. They have momentum. These can be more volatile - they don’t have the floor of strong cash flow

0	Megatrend and thematic drivers Megatrends include Health & Wellness Trends. Themes include Aesthetic Medical Devices, and Anti-Aging & Rejuvenation.	Weak multi-year price returns 2Y Excs Rtn is -128%, 3Y Excs Rtn is -165%	Not profitable at operating income level Op Inc LTMOperating Income, Last Twelve Months is -35 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -59%
1			Weak revenue growth Rev Chg LTMRevenue Change % Last Twelve Months (LTM) is -12%, Rev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is -18%, Rev Chg QQuarterly Revenue Change % is -8.2%
2			Not cash flow generative CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -35%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -35%
3			Valuation getting more expensive P/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is 124%
4			High stock price volatility Vol 12M is 1056%
5			Key risks VERO key risks include [1] severe financial distress with a very high probability of bankruptcy and [2] operational inefficiencies causing deteriorating gross margins.

0	Megatrend and thematic drivers Megatrends include Health & Wellness Trends. Themes include Aesthetic Medical Devices, and Anti-Aging & Rejuvenation.
1	Weak multi-year price returns 2Y Excs Rtn is -128%, 3Y Excs Rtn is -165%
2	Not profitable at operating income level Op Inc LTMOperating Income, Last Twelve Months is -35 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -59%
3	Weak revenue growth Rev Chg LTMRevenue Change % Last Twelve Months (LTM) is -12%, Rev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is -18%, Rev Chg QQuarterly Revenue Change % is -8.2%
4	Not cash flow generative CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -35%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -35%
5	Valuation getting more expensive P/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is 124%
6	High stock price volatility Vol 12M is 1056%
7	Key risks VERO key risks include [1] severe financial distress with a very high probability of bankruptcy and [2] operational inefficiencies causing deteriorating gross margins.

Valuation, Metrics & Events

null

	VERO	S&P 500
REVENUE GROWTH	VERY POOR
Rev LTM ($ Bil)	0.1
Rev Chg Q	-8.2%	7.3%
Rev Chg LTM	-12.4%	6.0%
Rev Chg 3Y Avg	-18.1%	5.5%
PROFITABILITY	VERY POOR
Op Inc LTM ($ Bil)	-0.0
CFO LTM ($ Bil)	-0.0
Net Inc LTM ($ Bil)	-0.1
Op Mgn LTM	-59.0%	18.8%
CFO/Rev LTM	-34.7%	20.4%
Net Inc Mgn	-92.8%	13.1%
VALUATION	VERY LOW
P/S	0.1	3.2
P/CFO	-0.2	16.0
P/FCF	-0.2	20.8
P/E	-0.1	23.5

AI Generated Analysis | Feedback

Metric	Value	Date	Source
Number of Countries with Operations	over 60	11102025	Link
Number of Direct Markets	9	11102025	Link
Percentage of Total Systems Revenue from Internal Lease Programs	approximately 20%	12312024	Link
Number of Employees	292	12312023	Link
Number of Aesthetic Device Platforms	11	11102025	Link
Number of Hair Restoration Systems	2	11102025	Link

null

VERO Stock

Return (1M):

Why The Stock Moved

Qualitative Assessment

AI Generated Analysis | Feedback

Following a review of Venus Concept's (VERO) performance between August 31, 2025, and December 18, 2025, the stock's approximate -17.6% movement can be attributed to several key factors:

1. Significant Q3 2025 Earnings Miss: The company reported a substantial non-GAAP earnings per share (EPS) loss of $12.14 for the third quarter of 2025, announced on November 13, 2025. This was significantly wider than the analyst estimate of a $3.68 loss per share.

2. Revenue Falling Short of Expectations: Venus Concept's Q3 2025 revenue of $13.78 million failed to meet analyst projections of $14.77 million, representing an 8% year-over-year decrease.

Stock Movement Drivers

Fundamental Drivers

The -22.9% change in VERO stock from 9/17/2025 to 12/17/2025 was primarily driven by a -27.4% change in the company's Shares Outstanding (Mil).

	9172025	12172025	Change
Stock Price ($)	2.36	1.82	-22.88%
Change Contribution By	LTM	LTM
Total Revenues ($ Mil)	60.11	58.88	-2.05%
P/S Multiple	0.06	0.06	0.32%
Shares Outstanding (Mil)	1.46	1.86	-27.42%
Cumulative Contribution			-28.68%

LTM = Last Twelve Months as of date shown

Market Drivers

9/17/2025 to 12/17/2025

	Return	Correlation
VERO	-22.9%
Market (SPY)	1.9%	28.5%
Sector (XLV)	12.1%	-8.9%

Fundamental Drivers

The -24.5% change in VERO stock from 6/18/2025 to 12/17/2025 was primarily driven by a -162.2% change in the company's Shares Outstanding (Mil).

	6182025	12172025	Change
Stock Price ($)	2.41	1.82	-24.48%
Change Contribution By	LTM	LTM
Total Revenues ($ Mil)	61.00	58.88	-3.48%
P/S Multiple	0.03	0.06	105.14%
Shares Outstanding (Mil)	0.71	1.86	-162.20%
Cumulative Contribution			-223.16%

LTM = Last Twelve Months as of date shown

Market Drivers

6/18/2025 to 12/17/2025

	Return	Correlation
VERO	-24.5%
Market (SPY)	12.7%	23.4%
Sector (XLV)	16.0%	-2.3%

Fundamental Drivers

The -47.9% change in VERO stock from 12/17/2024 to 12/17/2025 was primarily driven by a -162.2% change in the company's Shares Outstanding (Mil).

	12172024	12172025	Change
Stock Price ($)	3.49	1.82	-47.92%
Change Contribution By	LTM	LTM
Total Revenues ($ Mil)	67.20	58.88	-12.39%
P/S Multiple	0.04	0.06	55.86%
Shares Outstanding (Mil)	0.71	1.86	-162.20%
Cumulative Contribution			-184.94%

LTM = Last Twelve Months as of date shown

Market Drivers

12/17/2024 to 12/17/2025

	Return	Correlation
VERO	-47.9%
Market (SPY)	12.1%	7.1%
Sector (XLV)	11.9%	0.2%

Fundamental Drivers

The -96.2% change in VERO stock from 12/18/2022 to 12/17/2025 was primarily driven by a -370.0% change in the company's Shares Outstanding (Mil).

	12182022	12172025	Change
Stock Price ($)	47.85	1.82	-96.20%
Change Contribution By	LTM	LTM
Total Revenues ($ Mil)	107.84	58.88	-45.41%
P/S Multiple	0.18	0.06	-67.26%
Shares Outstanding (Mil)	0.40	1.86	-369.98%
Cumulative Contribution			-148.26%

LTM = Last Twelve Months as of date shown

Market Drivers

12/18/2023 to 12/17/2025

	Return	Correlation
VERO	-82.8%
Market (SPY)	44.9%	7.1%
Sector (XLV)	17.8%	1.5%

Return vs. Risk

Price Returns Compared

	2020	2021	2022	2023	2024	2025	Total [1]
Returns
VERO Return	-63%	-2%	-81%	-75%	-68%	-45%	-100%
Peers Return	�	�	-47%	-0%	-21%	20%	�
S&P 500 Return	16%	27%	-19%	24%	23%	14%	108%
Monthly Win Rates [3]
VERO Win Rate	42%	50%	42%	17%	33%	33%
Peers Win Rate	�	61%	40%	52%	40%	47%
S&P 500 Win Rate	58%	75%	42%	67%	75%	73%
Max Drawdowns [4]
VERO Max Drawdown	-64%	-31%	-90%	-81%	-75%	-93%
Peers Max Drawdown	�	�	-58%	-29%	-41%	-37%
S&P 500 Max Drawdown	-31%	-1%	-25%	-1%	-2%	-15%

[1] Cumulative total returns since the beginning of 2020
[2] Peers: BHC, ABBV, APYX, SKIN, CNMD.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2025 data is for the year up to 12/17/2025 (YTD)

How Low Can It Go

Unique Key	Event	VERO	S&P 500
2022 Inflation Shock	2022 Inflation Shock
2022 Inflation Shock% Loss	% Loss	-98.2%	-25.4%
2022 Inflation Shock% Gain to Breakeven	% Gain to Breakeven	5488.5%	34.1%
2022 Inflation ShockTime to Breakeven	Time to Breakeven	Not Fully Recovered days	464 days
2020 Covid Pandemic	2020 Covid Pandemic
2020 Covid Pandemic% Loss	% Loss	-79.6%	-33.9%
2020 Covid Pandemic% Gain to Breakeven	% Gain to Breakeven	391.0%	51.3%
2020 Covid PandemicTime to Breakeven	Time to Breakeven	Not Fully Recovered days	148 days
2018 Correction	2018 Correction
2018 Correction% Loss	% Loss	-98.1%	-19.8%
2018 Correction% Gain to Breakeven	% Gain to Breakeven	5291.3%	24.7%
2018 CorrectionTime to Breakeven	Time to Breakeven	Not Fully Recovered days	120 days

Compare to A, ATEC, CERS, BLLN, BNBX

In The Past

Venus Concept's stock fell -98.2% during the 2022 Inflation Shock from a high on 2/19/2021. A -98.2% loss requires a 5488.5% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth over time.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

About Venus Concept (VERO)

Venus Concept Inc., a medical technology company, develops, commercializes, and delivers minimally invasive and non-invasive medical aesthetic and hair restoration technologies, and related services in the United States and internationally. Its product portfolio includes aesthetic device platforms, including Venus Legacy, a noninvasive device used in dermatological and general surgical procedures for females; Venus Versa, a multi-application device used in aesthetic and cosmetic procedures; and Venus Viva, an advanced, portable, and fractional RF system for dermatological procedures requiring ablation and resurfacing of the skin. The company also offers Venus Fiore, a device that delivers non-thermal RF with massage and magnetic field pulses to treat various medical conditions; Venus Bliss, a device for non-invasive lipolysis of the abdomen and flanks in individuals with a body mass index of 30 or less; Venus Glow, a dermabrasion device used to improve skin appearance; and NeoGraft, an advanced hair restoration technology with an automated FUE and implantation system. In addition, it provides Venus Velocity and Venus Epileve for hair removal, permanent hair reduction, and treatment of pseudofolliculitis barbae; and ARTAS iX, a robotic system to assist physicians in identifying and extracting hair follicles units from the scalp during hair transplantation, creating recipient sites, and implanting the harvested hair follicles. The company is headquartered in Toronto, Canada.

AI Generated Analysis | Feedback

Here are 1-2 brief analogies for Venus Concept (VERO):

Align Technology for cosmetic clinics.
Intuitive Surgical for non-invasive cosmetic treatments.

AI Generated Analysis | Feedback

Venus Versa™: A versatile multi-treatment platform offering intense pulsed light (IPL) for skin rejuvenation, hair removal, and various radiofrequency (RF) applications for skin tightening and anti-aging.
Venus Legacy™: A non-invasive device that uses Multi-Polar Radio Frequency and Pulsed Electro Magnetic Fields to effectively reduce wrinkles, tighten skin, and diminish cellulite.
Venus Viva™ MD: A fractional radiofrequency (RF) system designed for advanced skin resurfacing, reducing the appearance of wrinkles, scars, and improving overall skin texture.
Venus Bliss™: Combines diode laser technology for non-invasive fat reduction with multi-polar radiofrequency for skin tightening and cellulite reduction on the body.
NeoGraft®: An automated Follicular Unit Extraction (FUE) and implantation system for minimally invasive hair restoration procedures.
ARTAS®: A robotic system that assists physicians in performing precise and efficient follicular unit extraction (FUE) for hair transplantation.
Venus Glow™: A dermal rejuvenation system utilizing a vacuum, 360-degree rotating tip, and saline jet to cleanse pores, remove impurities, and hydrate the skin.

AI Generated Analysis | Feedback

Venus Concept (symbol: VERO) primarily sells its medical aesthetic devices and related services to other businesses (B2B).

However, the company's customer base is highly fragmented, consisting of thousands of individual medical aesthetic practices, dermatology clinics, plastic surgery offices, and medical spas worldwide. These customers are typically private businesses and not large, publicly traded corporate entities.

Therefore, Venus Concept does not disclose specific "major customer companies" that are publicly traded with associated stock symbols, as no single customer or group of related customers accounts for a significant portion of the company's revenue.

AI Generated Analysis | Feedback

null

AI Generated Analysis | Feedback

Rajiv De Silva, Chief Executive Officer

Rajiv De Silva previously served as President, Chief Executive Officer, and Director of Endo International Plc, a publicly traded, multinational pharmaceutical corporation. He was also the President of Valeant Pharmaceuticals International (now Bausch Health), where he additionally served as Chief Operating Officer of the company's Specialty Pharmaceuticals business, including its dermatology and aesthetics unit. Prior to that, Mr. De Silva held various leadership positions within Novartis AG, including President of Novartis Pharma Canada. He began his career in healthcare at McKinsey & Company in 1995, where he rose to Partner.

Domenic Della Penna, Executive Vice President and Chief Financial Officer

Domenic Della Penna brings considerable expertise to Venus Concept, having held senior posts at several industry-leading multinationals such as Teva Pharmaceuticals, Diageo, and Nestle. Most recently, he was the CFO of Intellipharmaceutics International Inc., a Nasdaq and TSX listed public company. Mr. Della Penna also gained private equity experience through a successful mandate as CFO of Timothy's Coffees of The World. He has made significant contributions to numerous mergers, acquisitions, divestitures, financial systems, and organizational change mandates. He is a C.A., CPA, and holds an MBA from the Schulich School of Business at York University (Toronto).

Melissa Kang, Chief Product Officer

Melissa Kang has over 25 years of experience in marketing, sales management, consulting, and business development. She has owned her own business and managed global brands such as BOTOX Cosmetic®. She holds a BSc in Chemistry from the University of Western Ontario, an MBA from Queen's University, and is a CPA, CMA.

Michael Mandarello, Chief Legal Officer & Head of Strategy & Operations

Michael Mandarello brings more than 10 years of experience providing legal and strategic advice. He took on an expanded role overseeing corporate strategy and operational execution in February 2025.

Kirk Gunhus, Chief Revenue Officer

Kirk Gunhus was appointed Chief Revenue Officer in February 2025, with global responsibility for Venus Concept's sales efforts. He is a seasoned aesthetics industry professional with over 20 years of experience leading commercial organizations in international markets at companies such as Medicis, Zeltiq, Sientra, and MiraDry.

AI Generated Analysis | Feedback

Key Risks to Venus Concept (VERO)

Significant Financial Challenges and High Risk of Bankruptcy: Venus Concept faces substantial financial difficulties, including a consistent decline in total revenue, negative profitability with ongoing net losses, negative earnings per share (EPS), and a negative net margin. The company has high debt levels, with total debt obligations ranging between approximately $30.1 million and $35.5 million, and a debt-to-equity ratio of 15.93. Its limited liquidity, evidenced by a current ratio of 1.1 and low cash and cash equivalents, further exacerbates these concerns. An Altman Z-Score of -8.22 indicates a very high probability of bankruptcy, estimated at 86%.
Macroeconomic Headwinds and Customer Financing Pressures: The company's business operations are significantly impacted by "customer financing pressures, economic uncertainty and tight credit markets". These macroeconomic factors have consistently led to declining sales, particularly affecting the aesthetic capital equipment sector and the adoption of robotic systems in the Venus Hair business, with notable weakness in the U.S. market.
Operational Inefficiencies and Gross Margin Pressure: Venus Concept grapples with operational inefficiencies, resulting in persistent profitability issues and a negative operating margin. While the gross margin remains relatively healthy, it has shown deterioration, which is attributed to pricing pressure, unfavorable product mix shifts, and the impact of U.S. tariffs on imported devices.

AI Generated Analysis | Feedback

The clear emerging threat to Venus Concept (VERO) is the widespread adoption and increasing efficacy of GLP-1 agonist medications (e.g., Ozempic, Wegovy, Mounjaro) for weight loss and fat reduction. These pharmaceutical treatments offer patients a non-surgical and highly effective method for achieving significant weight reduction. As these medications become more accessible and prescribed, they pose a direct challenge to the demand for non-invasive body contouring and fat reduction devices, which constitute a significant portion of Venus Concept's product offerings.

AI Generated Analysis | Feedback

Venus Concept (symbol: VERO) operates primarily in the global medical aesthetic technology and hair restoration markets. The addressable markets for their main products and services are substantial, as detailed below:

Global Medical Aesthetics Market

The global medical aesthetics market was valued at approximately USD 25.88 billion in 2024 and is projected to reach around USD 87.84 billion by 2034, growing at a Compound Annual Growth Rate (CAGR) of 13% from 2024 to 2034.
Another estimate places the global market at USD 17.10 billion in 2025, projected to reach USD 27.92 billion by 2030, with a CAGR of 10.30%.
The global market for medical aesthetic devices was valued at USD 20.1 billion in 2023 and is forecast to grow at a CAGR of 11.3% to reach USD 37.9 billion by the end of 2029.

U.S. Medical Aesthetics Market

The U.S. aesthetic medicine market size was estimated at USD 37.94 billion in 2023 and is projected to grow at a CAGR of 13.4% from 2024 to 2030, reaching USD 90.82 billion by 2030.
The U.S. medical aesthetics market size was calculated at USD 9.82 billion in 2024 and is projected to be worth around USD 33.98 billion by 2034, growing at a CAGR of 13.2% from 2024 to 2034.
North America held more than 40% of the global revenue with a market size of USD 6.338 billion in 2024.

Global Hair Restoration Market

The global hair restoration market size was estimated at USD 6,463.0 million in 2023 and is projected to reach USD 18,923.4 million by 2030, growing at a CAGR of 16.6% from 2024 to 2030.
The global hair restoration services market size was approximately USD 7.52 billion in 2024 and is predicted to grow to around USD 34.17 billion by 2034, with a CAGR of roughly 16.35% between 2025 and 2034.
Another estimate states the global hair restoration market is valued at USD 7.46 billion in 2025 and is expected to reach USD 21.73 billion by 2032, exhibiting a CAGR of 16.5% from 2025 to 2032.

U.S. Hair Restoration Market

The hair transplant market in the U.S. dominated the industry with a revenue share of 80.33% in 2023.

Global Skin Resurfacing Market

The global skin resurfacing market was valued at USD 5.6 billion in 2024 and is expected to reach USD 9.0 billion by 2030, confirming a robust CAGR of 8.1%.
The global skin resurfacing devices market is valued at USD 358.05 million in 2025 and is forecast to reach USD 538.38 million by 2030, advancing at an 8.5% CAGR.

Global Body Contouring Market

The global body contouring devices market size was estimated at USD 1.75 billion in 2024 and is expected to hit around USD 6.67 billion by 2034, growing at a CAGR of 14.32% from 2025 to 2034.
The global non-invasive body contouring devices market is forecast to reach USD 5,195.9 million by 2030, at a CAGR of 6.7% during the forecast period 2024-2030.
The global non-invasive fat reduction market size is calculated at USD 1.87 billion in 2024 and is projected to reach around USD 8.74 billion by 2034, expanding at a CAGR of 17.04% between 2025 and 2034.

U.S. Body Contouring Market

The U.S. body contouring devices market size was exhibited at USD 520 million in 2024 and is predicted to surpass around USD 1,990 million by 2034, growing at a CAGR of 14.36% from 2025 to 2034.
North America dominated the global body contouring devices market with the largest market share of 78% in 2024.

Global Cellulite Reduction Market

The global cellulite treatment market size was valued at USD 2.4 billion in 2024 and is expected to grow from USD 2.6 billion in 2025 to USD 6.5 billion in 2034, at a CAGR of 10.7%.
The global cellulite reduction devices market size was over USD 361.8 million in 2025 and is estimated to reach USD 955.9 million by the end of 2035, expanding at a CAGR of 11.4% during the forecast timeline, i.e., 2026-2035.

U.S. Cellulite Reduction Market

In 2024, the U.S. cellulite treatment market accounted for USD 763.7 million in market revenue and is anticipated to grow at a CAGR of 10% between the 2025 to 2034 period.

Global Acne Treatment Market

The global acne treatment market size is estimated at USD 7.2 billion in 2024 and is forecasted to reach USD 12.44 billion by 2034, advancing at a CAGR of 5.6% between 2024 and 2034.
Another report states the global acne treatment market size was valued at USD 11.62 billion in 2024 and is projected to grow from USD 12.19 billion in 2025 to USD 17.48 billion by 2032, exhibiting a CAGR of 5.3% during the forecast period.

North America Acne Treatment Market

North America dominated the acne treatment market with a market share of 49.14% in 2023.
The North America acne treatment market size was USD 5.70 billion in 2024.
The U.S. acne treatment market size was exhibited at USD 2.79 billion in 2024 and is projected to be worth around USD 4.88 billion by 2034, growing at a CAGR of 5.84% from 2025 to 2034.

AI Generated Analysis | Feedback

Venus Concept (VERO) is anticipated to drive future revenue growth over the next 2-3 years through several key initiatives:

Launch and global rollout of Venus NOVA: The company recently received FDA 510(k) clearance for its next-generation multi-application platform, Venus NOVA, with U.S. commercial availability slated for December 2025 and a global rollout planned for 2026. This new platform, a key part of Venus Concept's strategic turnaround and new R&D strategy, is designed for non-invasive body, face, and skin treatments, integrating technologies like Adaptive EMS, MP² RF+PEMF, and IoT connectivity. It is also positioned to address the growing market segment of patient needs linked to GLP-1 medication use.
Expansion into international markets: Venus Concept expects to see future revenue growth from strategic expansion in international markets. The company has introduced and certified key products in markets such as Australia and India. Furthermore, a 60% increase in sales to distributors in Q3 2024 suggests successful repositioning in these international markets. The global rollout of Venus NOVA in 2026 will also contribute to this international expansion.
Strategic shift towards cash system sales: Venus Concept is prioritizing cash system sales, a strategy that has proven effective, with cash-based sales representing a significant 76% of U.S. system sales in Q3 2024. This shift aims to improve the company's financial performance and reduce its reliance on lease revenue, which experienced a 39% decrease.
Growth of recently launched products like Venus Versa Pro: The commercial launch of the multi-application Venus Versa Pro in the United States in November 2023 is expected to contribute to revenue. This platform supports 10 different applicators for a broad range of aesthetic conditions and represents the first platform product under the company's Venus Aesthetic Intelligence ("Venus AI") rebrand, with additional product launches under this branding anticipated in 2024.

AI Generated Analysis | Feedback

Share Issuance

  In December 2020, Venus Concept announced the pricing of a public offering of common stock and warrants, expecting to raise approximately $22.5 million for general corporate purposes, including funding research and development activities.
  In May 2020, the company completed a private placement of approximately $22.25 million in securities, including common stock, preferred stock, and warrants, to a group of investors including EW Healthcare Partners, HealthQuest Capital, and SEDCO Capital.
  Throughout 2025, Venus Concept conducted several registered direct offerings, including approximately $1.1 million in April 2025, and an additional $1.57 million in April 2025, with gross proceeds from both offerings totaling approximately $2.7 million for general corporate purposes. The company also had a registered direct offering in June 2025 for $1.15 million with potential for an additional $2.3 million from warrants.

Inbound Investments

  Venus Concept secured approximately $22.25 million in May 2020 through a private placement of securities to strategic healthcare industry investors.
  The company received an additional $2 million in funding in April 2025 through its ongoing Bridge Financing agreement with Madryn Health Partners.
  Venus Concept completed several debt-to-equity exchange transactions, including $11.0 million of subordinated convertible notes for preferred stock in April 2025, $6.5 million in July 2025, and $11.48 million in October 2025. These transactions reduced total debt obligations by 14% and 24% respectively, bolstering financial flexibility.

Outbound Investments

  In June 2025, Venus Concept entered into a definitive agreement to sell its Venus Hair business to Meta Healthcare Group for $20 million in an all-cash transaction. This divestiture aims to enhance the company's financial stability and allow it to focus on its core medical aesthetics operations.

Better Bets than Venus Concept (VERO)

	VERO	Better Performance than VERO
Metric	Value	INDUSTRY: Life Sciences Tools & Services
Rev Chg LTM	-12.4%	NTRA (38.2%), A (4.5%), IQV (3.8%), TMO (3.2%), DHR (2.2%)
Rev Chg 3Y Avg	-18.1%	NTRA (40.2%), IQV (3.6%), A (0.8%), TMO (-0.3%), DHR (-1.9%)
Op Mgn LTM	-59.0%	A (21.3%), DHR (19.0%), TMO (18.4%), IQV (14.2%), NTRA (-16.6%)
CFO/Rev LTM	-34.7%	DHR (26.0%), A (22.0%), IQV (17.6%), TMO (17.5%), NTRA (9.2%)
FCF/Rev LTM	-35.2%	DHR (20.7%), A (16.0%), TMO (14.0%), IQV (13.9%), NTRA (4.4%)
Total Yield	-1277.3%	A (4.5%), IQV (4.0%), TMO (3.6%), DHR (2.5%), NTRA (-1.4%)
P/S	0.1	IVF (0.1)

	VERO	Better Performance than VERO
Metric	Value	SECTOR: Health Care
Rev Chg LTM	-12.4%	LLY (36.8%), UNH (10.5%), ABBV (7.4%), JNJ (5.1%), MRK (1.7%)
Rev Chg 3Y Avg	-18.1%	LLY (23.4%), UNH (11.4%), JNJ (6.1%), MRK (2.9%), ABBV (1.2%)
Op Mgn LTM	-59.0%	LLY (43.0%), MRK (34.9%), JNJ (26.2%), ABBV (24.1%), UNH (6.1%)
CFO/Rev LTM	-34.7%	ABBV (35.0%), MRK (26.6%), JNJ (26.3%), LLY (20.5%), UNH (4.8%)
FCF/Rev LTM	-35.2%	ABBV (33.0%), MRK (20.3%), JNJ (20.3%), UNH (4.0%), LLY (-0.1%)
Total Yield	-1277.3%	MRK (13.0%), JNJ (8.4%), UNH (8.1%), ABBV (3.4%), LLY (2.7%)
P/S	0.1	PIII (0.0), OMI (0.0), CYH (0.0), VERU (0.1), AGL (0.1)

	VERO	Better Performance than VERO
Metric	Value	ALL OTHER SECTORS
Rev Chg LTM	-12.4%	NVDA (65.2%), MSFT (15.6%), GOOGL (13.4%), AMZN (10.9%), AAPL (6.0%)
Rev Chg 3Y Avg	-18.1%	NVDA (91.6%), MSFT (13.2%), AMZN (11.3%), GOOGL (11.0%), AAPL (1.8%)
Op Mgn LTM	-59.0%	NVDA (58.8%), MSFT (46.3%), GOOGL (32.2%), AAPL (31.9%), AMZN (11.4%)
CFO/Rev LTM	-34.7%	MSFT (50.0%), NVDA (44.4%), GOOGL (39.3%), AAPL (26.6%), AMZN (18.1%)
FCF/Rev LTM	-35.2%	NVDA (41.3%), MSFT (26.6%), AAPL (23.5%), GOOGL (19.1%), AMZN (2.0%)
Total Yield	-1277.3%	GOOGL (4.6%), MSFT (3.4%), AMZN (3.0%), AAPL (3.0%), NVDA (2.2%)
P/S	0.1	SNEX (0.0), WKC (0.0), GOLD (0.1), ARKO (0.1), UNFI (0.1)

null

Latest Trefis Analyses

	Title	Topic
0	DASHBOARDS
1	Venus Concept Stock Jump Looks Great, But How Secure Is That Gain?	Return

	Title
0	ARTICLES

Trade Ideas

Select past ideas related to VERO. For more, see Trefis Trade Ideas.

Unique Key	Date	Ticker	Company	Category	Trade Strategy	6M Fwd Rtn	12M Fwd Rtn	12M Max DD
CRL_11142025_Dip_Buyer_FCFYield	11142025	CRL	Charles River Laboratories International	Dip Buy	DB \| FCFY OPMDip Buy with High FCF Yield and High Margin Buying dips for companies with high FCF yield and meaningfully high operating margin	16.8%	16.8%	-3.7%
GDRX_11142025_Dip_Buyer_High_CFO_Margins_ExInd_DE	11142025	GDRX	GoodRx	Dip Buy	DB \| CFO/Rev \| Low D/EDip Buy with High Cash Flow Margins Buying dips for companies with significant cash flows from operations and reasonable debt / market cap	-6.4%	-6.4%	-11.8%
ASTH_11142025_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG	11142025	ASTH	Astrana Health	Dip Buy	DB \| FCF Yield \| Low D/EDip Buy with High Free Cash Flow Yield Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap	5.2%	5.2%	-5.5%
SGRY_11142025_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG	11142025	SGRY	Surgery Partners	Dip Buy	DB \| FCF Yield \| Low D/EDip Buy with High Free Cash Flow Yield Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap	3.4%	3.4%	-1.4%
TFX_11072025_Dip_Buyer_FCFYield	11072025	TFX	Teleflex	Dip Buy	DB \| FCFY OPMDip Buy with High FCF Yield and High Margin Buying dips for companies with high FCF yield and meaningfully high operating margin	14.4%	14.4%	-5.1%

Unique Key	Date	Ticker	Company	Category	Trade Strategy	6M Fwd Rtn	12M Fwd Rtn	12M Max DD
CRL_11142025_Dip_Buyer_FCFYield	11142025	CRL	Charles River Laboratories International	Dip Buy	DB \| FCFY OPMDip Buy with High FCF Yield and High Margin Buying dips for companies with high FCF yield and meaningfully high operating margin	16.8%	16.8%	-3.7%
GDRX_11142025_Dip_Buyer_High_CFO_Margins_ExInd_DE	11142025	GDRX	GoodRx	Dip Buy	DB \| CFO/Rev \| Low D/EDip Buy with High Cash Flow Margins Buying dips for companies with significant cash flows from operations and reasonable debt / market cap	-6.4%	-6.4%	-11.8%
ASTH_11142025_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG	11142025	ASTH	Astrana Health	Dip Buy	DB \| FCF Yield \| Low D/EDip Buy with High Free Cash Flow Yield Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap	5.2%	5.2%	-5.5%
SGRY_11142025_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG	11142025	SGRY	Surgery Partners	Dip Buy	DB \| FCF Yield \| Low D/EDip Buy with High Free Cash Flow Yield Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap	3.4%	3.4%	-1.4%
TFX_11072025_Dip_Buyer_FCFYield	11072025	TFX	Teleflex	Dip Buy	DB \| FCFY OPMDip Buy with High FCF Yield and High Margin Buying dips for companies with high FCF yield and meaningfully high operating margin	14.4%	14.4%	-5.1%

Recent Active Movers

1 Day Top Gainers

Ticker	Company	Mkt Cap (B)	1D Rtn	YTD Rtn
UDMY	Udemy	0.9	12.7%	-26.5%
TWO	Two Harbors Investment	1.2	12.1%	8.5%
IOVA	Iovance Biotherapeutics	0.9	12.0%	-65.9%
KOD	Kodiak Sciences	1.4	11.8%	171.1%
RXRX	Recursion Pharmaceuticals	2.1	11.4%	-30.8%
TTC	Toro	7.9	10.7%	2.0%
HUT	Hut 8	4.2	9.0%	96.0%
TPL	Texas Pacific Land	20.3	7.6%	-19.7%
AXGN	Axogen	1.5	7.0%	90.5%
SSII	SS Innovations International	1.1	6.7%	-25.6%

1 Day Top Losers

Ticker	Company	Mkt Cap (B)	1D Rtn	YTD Rtn
NOW	ServiceNow	32.5	-80.0%	-85.2%
FDMT	4D Molecular Therapeutics	0.5	-20.1%	65.4%
IMNM	Immunome	1.7	-15.8%	86.3%
HNRG	Hallador Energy	0.7	-15.2%	51.2%
AMPX	Amprius Technologies	1.1	-14.6%	213.6%
BNTC	Benitec Biopharma	0.4	-13.1%	-14.6%
FLNC	Fluence Energy	2.4	-12.9%	16.9%
IMSR	Terrestrial Energy	0.7	-12.6%
BE	Bloom Energy	18.1	-12.1%	246.6%
BW	Babcock & Wilcox Enterprises	0.5	-12.1%	182.9%

1 Week Top Gainers

Ticker	Company	Mkt Cap (B)	1W Rtn	YTD Rtn
TLRY	Tilray Brands	13.7	55.9%	-3.2%
PL	Planet Labs PBC	5.0	27.3%	307.7%
EEX	Emerald	0.9	25.9%	-2.8%
EVCM	EverCommerce	2.2	17.2%	10.4%
CNL	Collective Mining	1.1	15.8%	229.3%
ENVA	Enova International	4.1	15.8%	70.8%
IMVT	Immunovant	4.6	14.5%	8.9%
QURE	uniQure	1.3	14.3%	30.4%
INNV	InnovAge	0.8	14.2%	49.6%
PGEN	Precigen	1.2	13.4%	255.4%

1 Week Top Losers

Ticker	Company	Mkt Cap (B)	1W Rtn	YTD Rtn
NOW	ServiceNow	32.5	-81.7%	-85.2%
RZLT	Rezolute	0.2	-81.6%	-59.0%
FRMI	Fermi	6.3	-41.1%
LENZ	LENZ Therapeutics	0.5	-34.6%	-43.3%
BETR	Better Home & Finance	0.5	-30.9%	292.0%
LWLG	Lightwave Logic	0.4	-29.5%	41.4%
APLD	Applied Digital	5.6	-29.0%	188.0%
CRWV	CoreWeave	31.4	-26.8%
WULF	TeraWulf	4.5	-26.6%	104.4%
BW	Babcock & Wilcox Enterprises	0.5	-26.5%	182.9%

1 Month Top Gainers

Ticker	Company	Mkt Cap (B)	1M Rtn	YTD Rtn
OLMA	Olema Pharmaceuticals	2.8	282.6%	459.2%
WVE	WAVE Life Sciences	2.7	128.5%	32.1%
ALMS	Alumis	0.8	89.8%	34.6%
NUVB	Nuvation Bio	2.9	82.4%	220.3%
SEMR	SEMrush	1.8	75.7%	-0.2%
TE	T1 Energy	0.8	70.4%
ANF	Abercrombie & Fitch	5.6	68.4%	-21.6%
CBLL	CeriBell	0.8	67.5%	-16.6%
FTRE	Fortrea	1.5	65.4%	-13.2%
VERA	Vera Therapeutics	3.1	64.7%	14.8%

1 Month Top Losers

Ticker	Company	Mkt Cap (B)	1M Rtn	YTD Rtn
NOW	ServiceNow	32.5	-81.3%	-85.2%
RZLT	Rezolute	0.2	-80.3%	-59.0%
JANX	Janux Therapeutics	0.9	-50.9%	-73.7%
FRMI	Fermi	6.3	-50.6%
AGIO	Agios Pharmaceuticals	1.5	-43.6%	-22.6%
IMSR	Terrestrial Energy	0.7	-38.9%
LENZ	LENZ Therapeutics	0.5	-36.3%	-43.3%
LWLG	Lightwave Logic	0.4	-36.3%	41.4%
UAMY	United States Antimony	0.5	-33.7%	156.5%
BETR	Better Home & Finance	0.5	-33.6%	292.0%

Recent Active Movers

1 Day Top Gainers

Ticker	Company	Mkt Cap (B)	1D Rtn	YTD Rtn
UDMY	Udemy	0.9	12.7%	-26.5%
TWO	Two Harbors Investment	1.2	12.1%	8.5%
IOVA	Iovance Biotherapeutics	0.9	12.0%	-65.9%
KOD	Kodiak Sciences	1.4	11.8%	171.1%
RXRX	Recursion Pharmaceuticals	2.1	11.4%	-30.8%
TTC	Toro	7.9	10.7%	2.0%
HUT	Hut 8	4.2	9.0%	96.0%
TPL	Texas Pacific Land	20.3	7.6%	-19.7%
AXGN	Axogen	1.5	7.0%	90.5%
SSII	SS Innovations International	1.1	6.7%	-25.6%

1 Day Top Losers

Ticker	Company	Mkt Cap (B)	1D Rtn	YTD Rtn
NOW	ServiceNow	32.5	-80.0%	-85.2%
FDMT	4D Molecular Therapeutics	0.5	-20.1%	65.4%
IMNM	Immunome	1.7	-15.8%	86.3%
HNRG	Hallador Energy	0.7	-15.2%	51.2%
AMPX	Amprius Technologies	1.1	-14.6%	213.6%
BNTC	Benitec Biopharma	0.4	-13.1%	-14.6%
FLNC	Fluence Energy	2.4	-12.9%	16.9%
IMSR	Terrestrial Energy	0.7	-12.6%
BE	Bloom Energy	18.1	-12.1%	246.6%
BW	Babcock & Wilcox Enterprises	0.5	-12.1%	182.9%

1 Week Top Gainers

Ticker	Company	Mkt Cap (B)	1W Rtn	YTD Rtn
TLRY	Tilray Brands	13.7	55.9%	-3.2%
PL	Planet Labs PBC	5.0	27.3%	307.7%
EEX	Emerald	0.9	25.9%	-2.8%
EVCM	EverCommerce	2.2	17.2%	10.4%
CNL	Collective Mining	1.1	15.8%	229.3%
ENVA	Enova International	4.1	15.8%	70.8%
IMVT	Immunovant	4.6	14.5%	8.9%
QURE	uniQure	1.3	14.3%	30.4%
INNV	InnovAge	0.8	14.2%	49.6%
PGEN	Precigen	1.2	13.4%	255.4%

1 Week Top Losers

Ticker	Company	Mkt Cap (B)	1W Rtn	YTD Rtn
NOW	ServiceNow	32.5	-81.7%	-85.2%
RZLT	Rezolute	0.2	-81.6%	-59.0%
FRMI	Fermi	6.3	-41.1%
LENZ	LENZ Therapeutics	0.5	-34.6%	-43.3%
BETR	Better Home & Finance	0.5	-30.9%	292.0%
LWLG	Lightwave Logic	0.4	-29.5%	41.4%
APLD	Applied Digital	5.6	-29.0%	188.0%
CRWV	CoreWeave	31.4	-26.8%
WULF	TeraWulf	4.5	-26.6%	104.4%
BW	Babcock & Wilcox Enterprises	0.5	-26.5%	182.9%

Peer Comparisons for Venus Concept

Peers to compare with:

Financials

	VERO	BHC	ABBV	APYX	SKIN	CNMD	Median
Name	Venus Co.	Bausch H.	AbbVie	Apyx Med.	Beauty H.	Conmed
Mkt Price	1.82	6.82	224.31	3.65	1.50	39.80	5.24
Mkt Cap	0.0	2.5	396.8	0.1	0.2	1.2	0.7
Rev LTM	59	9,858	59,644	48	302	1,347	825
Op Inc LTM	-35	1,886	14,366	-10	-28	118	54
FCF LTM	-21	1,104	19,684	-9	34	149	92
FCF 3Y Avg	-15	450	20,012	-12	9	118	63
CFO LTM	-20	1,506	20,860	-8	39	168	103
CFO 3Y Avg	-15	780	20,962	-11	18	135	77

Growth & Margins

	VERO	BHC	ABBV	APYX	SKIN	CNMD	Median
Name	Venus Co.	Bausch H.	AbbVie	Apyx Med.	Beauty H.	Conmed
Rev Chg LTM	-12.4%	7.1%	7.4%	-1.3%	-13.1%	4.6%	1.6%
Rev Chg 3Y Avg	-18.1%	6.4%	1.2%	-0.5%	-3.5%	8.1%	0.3%
Rev Chg Q	-8.2%	5.3%	9.1%	12.1%	-10.3%	6.7%	6.0%
QoQ Delta Rev Chg LTM	-2.0%	1.3%	2.3%	3.0%	-2.6%	1.6%	1.5%
Op Mgn LTM	-59.0%	19.1%	24.1%	-19.8%	-9.3%	8.8%	-0.3%
Op Mgn 3Y Avg	-45.6%	18.2%	27.0%	-34.8%	-20.3%	10.0%	-5.1%
QoQ Delta Op Mgn LTM	-5.1%	0.1%	0.6%	6.6%	4.7%	-4.2%	0.3%
CFO/Rev LTM	-34.7%	15.3%	35.0%	-17.6%	12.8%	12.4%	12.6%
CFO/Rev 3Y Avg	-21.8%	8.0%	37.0%	-22.8%	5.5%	10.4%	6.8%
FCF/Rev LTM	-35.2%	11.2%	33.0%	-19.8%	11.3%	11.1%	11.1%
FCF/Rev 3Y Avg	-22.1%	4.4%	35.3%	-24.3%	3.1%	9.1%	3.7%

Valuation

	VERO	BHC	ABBV	APYX	SKIN	CNMD	Median
Name	Venus Co.	Bausch H.	AbbVie	Apyx Med.	Beauty H.	Conmed
Mkt Cap	0.0	2.5	396.8	0.1	0.2	1.2	0.7
P/S	0.1	0.2	6.9	1.8	0.8	1.1	1.0
P/EBIT	-	1.4	90.2	-10.4	98.3	12.3	12.3
P/E	-0.1	24.4	171.5	-6.0	-21.5	22.7	11.3
P/CFO	-0.2	1.6	19.6	-10.4	6.5	8.7	4.1
Total Yield	-1,277.3%	4.1%	3.4%	-16.7%	-4.7%	6.1%	-0.6%
Dividend Yield	0.0%	0.0%	2.8%	0.0%	0.0%	1.7%	0.0%
FCF Yield 3Y Avg	-	18.1%	6.2%	-20.0%	2.3%	6.3%	6.2%
D/E	-	9.1	0.2	0.4	1.5	0.6	0.6
Net D/E	-	8.4	0.2	0.2	0.6	0.6	0.6

Returns

	VERO	BHC	ABBV	APYX	SKIN	CNMD	Median
Name	Venus Co.	Bausch H.	AbbVie	Apyx Med.	Beauty H.	Conmed
1M Rtn	5.8%	11.3%	-4.1%	-9.4%	18.1%	-4.4%	0.8%
3M Rtn	-22.9%	-0.1%	2.3%	65.9%	-37.2%	-21.2%	-10.7%
6M Rtn	-24.5%	10.4%	22.9%	113.5%	2.7%	-23.3%	6.5%
12M Rtn	-47.9%	-11.2%	32.4%	122.6%	-6.8%	-43.4%	-9.0%
3Y Rtn	-96.2%	-4.3%	56.0%	82.5%	-84.3%	-51.8%	-28.1%
1M Excs Rtn	5.1%	10.5%	-4.9%	-10.2%	17.4%	-5.1%	0.1%
3M Excs Rtn	-23.6%	-2.4%	0.4%	61.6%	-38.1%	-23.9%	-13.0%
6M Excs Rtn	-36.9%	-2.0%	10.5%	101.1%	-9.6%	-35.7%	-5.8%
12M Excs Rtn	-63.9%	-23.8%	22.8%	106.2%	-16.1%	-55.5%	-19.9%
3Y Excs Rtn	-164.9%	-79.3%	-17.0%	23.7%	-154.0%	-124.1%	-101.7%

Financials

Annual
Quarterly

$ Mil \| FY: 12/31	LTM	2024	2023	2022	2021	2020	2019
Period End	9/30/2025	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019
Filing Date	11/13/2025	3/31/2025	4/1/2024	3/27/2023	3/28/2022	3/29/2021	3/30/2020
Key Financials
Total Revenue	59	65	76	99	106	78	110
EBITDA	-45	-36	-26	-35	-13	-68	-31
Operating Income	-35	-27	-28	-35	-18	-40	-30
Net Income	-55	-47	-37	-44	-23	-82	-41
EPS	-48.84	-71.21	-68.47	-109.34	-69.30	-384.45	-787.05
Growth Rates
Total Revenue Growth	-12.4%	-15.1%	-23.3%	-5.8%	35.4%	-29.3%	402.9%
EBITDA Growth	-21.1%	-38.0%	26.0%	-170.6%	81.0%	-124.2%	-19.1%
Operating Income Growth	-23.4%	4.0%	18.8%	-98.8%	56.6%	-33.6%	-16.9%
Net Income Growth	-8.9%	-26.2%	14.8%	-89.9%	71.8%	-101.2%	-41.4%
Margins
EBITDA Margin	-77.1%	-55.6%	-34.2%	-35.5%	-12.3%	-87.8%	-27.7%
Operating Income Margin	-59.0%	-41.9%	-37.1%	-35.1%	-16.6%	-51.8%	-27.4%
Net Income Margin	-92.8%	-72.5%	-48.8%	-43.9%	-21.8%	-104.7%	-36.8%
Cash & Debt
Total Cash	4	4	5	12	31	34	16
Total Debt	33	43	80	84	78	80	69
Net Debt / (Cash)	28	39	74	72	47	45	53
Cash Flows
Net Cash from Operations	-20	-11	-13	-27	-20	-29	-40
Free Cash from Operations	-21	-11	-13	-27	-20	-29	-41
Returns to Shareholders
Dividends	0	-0	-0	-0	-0	-0	-0
Share Repurchases	-0	-0	-0	-0	-0	-0	-0

null

Segment Financials

Revenue by Segment

$ Mil	2024	2023	2022	2021	2020
Single Segment	76
Products - Other		13	13	11	7
Products - Systems		48	43	29	32
Services		3	4	5	7
Venus Prime / Subscription - Systems		35	45	33	65
Total	76	99	106	78	110

Price Behavior

Price Behavior

Market Price	$1.82
Market Cap ($ Bil)	0.0
First Trading Date	10/12/2017
Distance from 52W High	-79.6%
	50 Days	200 Days
DMA Price	$2.04	$2.46
DMA Trend	down	down
Distance from DMA	-11.0%	-26.0%
	3M	1YR
Volatility	106.3%	1,062.4%
Downside Capture	231.76	135.10
Upside Capture	79.44	54.61
Correlation (SPY)	23.7%	7.1%

VERO Betas & Captures as of 11/30/2025

	1M	2M	3M	6M	1Y	3Y
Beta	3.21	2.51	2.33	2.14	3.75	2.46
Up Beta	8.47	4.25	4.43	3.99	15.17	10.96
Down Beta	6.47	2.50	2.86	2.88	-0.81	-0.32
Up Capture	85%	128%	94%	58%	46%	-4%
Bmk +ve Days	13	26	39	74	142	427
Stock +ve Days	10	17	28	50	105	315
Down Capture	174%	238%	184%	161%	118%	97%
Bmk -ve Days	7	16	24	52	107	323
Stock -ve Days	8	22	30	63	128	405

[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively

1Y 5Y 10Y

Based On 1-Year Data

		Comparison of VERO With Other Asset Classes (Last 1Y)
	VERO	Sector ETF	Equity	Gold	Commodities	Real Estate	Bitcoin
Annualized Return	-54.9%	10.5%	12.1%	61.5%	2.2%	-2.2%	-12.7%
Annualized Volatility	1,056.1%	17.4%	19.7%	19.3%	15.9%	17.7%	35.4%
Sharpe Ratio	0.93	0.41	0.46	2.36	-0.05	-0.28	-0.17
Correlation With Other Assets		0.2%	7.1%	6.7%	7.5%	-0.0%	11.1%

ETFs used for asset classes: Sector ETF = XLV, Equity = SPY, Gold = GLD, Commodities = DBC, Real Estate = VNQ, and Bitcoin = BTCUSD
Smart multi-asset allocation framework can stack odds in your favor. Learn How

Based On 5-Year Data

		Comparison of VERO With Other Asset Classes (Last 5Y)
	VERO	Sector ETF	Equity	Gold	Commodities	Real Estate	Bitcoin
Annualized Return	-65.3%	8.1%	14.4%	18.3%	11.4%	4.8%	36.3%
Annualized Volatility	486.0%	14.5%	17.1%	15.5%	18.9%	18.9%	48.9%
Sharpe Ratio	0.33	0.38	0.68	0.95	0.49	0.17	0.63
Correlation With Other Assets		2.7%	7.0%	5.0%	3.7%	2.0%	5.5%

Based On 10-Year Data

		Comparison of VERO With Other Asset Classes (Last 10Y)
	VERO	Sector ETF	Equity	Gold	Commodities	Real Estate	Bitcoin
Annualized Return	-68.8%	9.9%	14.5%	14.6%	6.1%	5.4%	70.7%
Annualized Volatility	387.9%	16.7%	18.0%	14.7%	17.7%	20.8%	55.9%
Sharpe Ratio	0.19	0.49	0.69	0.82	0.27	0.23	0.91
Correlation With Other Assets		4.2%	7.9%	4.6%	5.0%	3.7%	3.9%

Short Interest

Short Interest: As Of Date	11282025
Short Interest: Shares Quantity	144,013
Short Interest: % Change Since 11152025	-54.5%
Average Daily Volume	43,592
Days-to-Cover Short Interest	3.30
Basic Shares Quantity	1,859,000
Short % of Basic Shares	7.7%

Returns Analyses

	Title
0	Venus Concept Stock Jump Looks Great, But How Secure Is That Gain?

Earnings Returns History

Expand for More

	Forward Returns
Earnings Date	1D Returns	5D Returns	21D Returns
11/13/2025	-8.0%	1.1%	-10.7%
8/14/2025	-5.3%	-0.8%	-6.9%
3/31/2025	1.5%	-14.2%	-11.5%
11/13/2024	-10.0%	-16.2%	-1.5%
8/13/2024	-11.9%	-3.2%	-15.7%
4/1/2024	2.7%	5.5%	-5.9%
11/14/2023	-0.7%	-8.9%	-48.0%
8/14/2023	4.3%	-0.2%	-11.0%
...
SUMMARY STATS
# Positive	6	7	6
# Negative	13	12	13
Median Positive	3.2%	5.8%	13.4%
Median Negative	-8.0%	-15.3%	-15.7%
Max Positive	4.8%	12.0%	46.2%
Max Negative	-24.3%	-44.6%	-48.0%

	Forward Returns
11/13/2025	-8.0%	1.1%	-10.7%
8/14/2025	-5.3%	-0.8%	-6.9%
3/31/2025	1.5%	-14.2%	-11.5%
11/13/2024	-10.0%	-16.2%	-1.5%
8/13/2024	-11.9%	-3.2%	-15.7%
4/1/2024	2.7%	5.5%	-5.9%
11/14/2023	-0.7%	-8.9%	-48.0%
8/14/2023	4.3%	-0.2%	-11.0%
5/15/2023	-24.3%	-44.6%	-40.4%
2/7/2023	-15.0%	-21.7%	-41.4%
11/10/2022	3.6%	-22.5%	46.2%
8/12/2022	-12.0%	-28.9%	22.1%
3/28/2022	2.9%	10.1%	-29.3%
11/12/2021	-8.9%	-23.6%	-32.5%
8/13/2021	-2.4%	-14.4%	4.8%
3/29/2021	-1.8%	0.4%	-17.8%
11/16/2020	-0.5%	12.0%	2.9%
7/16/2020	4.8%	5.8%	0.3%
3/30/2020	-2.5%	11.5%	30.8%
SUMMARY STATS
# Positive	6	7	6
# Negative	13	12	13
Median Positive	3.2%	5.8%	13.4%
Median Negative	-8.0%	-15.3%	-15.7%
Max Positive	4.8%	12.0%	46.2%
Max Negative	-24.3%	-44.6%	-48.0%

SEC Filings

Expand for More

Report Date	Filing Date	Filing
9302025	11132025	10-Q 9/30/2025
6302025	8142025	10-Q 6/30/2025
3312025	5152025	10-Q 3/31/2025
12312024	3312025	10-K 12/31/2024
9302024	11132024	10-Q 9/30/2024
6302024	8132024	10-Q 6/30/2024
3312024	5152024	10-Q 3/31/2024
12312023	4012024	10-K 12/31/2023
9302023	11142023	10-Q 9/30/2023
6302023	8142023	10-Q 6/30/2023
3312023	5152023	10-Q 3/31/2023
12312022	3272023	10-K 12/31/2022
9302022	11102022	10-Q 9/30/2022
6302022	8122022	10-Q 6/30/2022
3312022	5122022	10-Q 3/31/2022
12312021	3282022	10-K 12/31/2021

Industry Resources

Health Care Resources

U.S. National Library of Medicine

Health Data Management

FDA Tracker

External Quote Links

0	Y Finance	Barrons
1	TradingView	Morningstar
2	SeekingAlpha	ValueLine
3	Motley Fool	Robinhood
4	CNBC	Etrade
5	MarketWatch	Unusual Whales
6	YCharts	Perplexity Finance
7	FinViz

Prefer one of these to Trefis? Tell us why.

Venus Concept (VERO)

Market Price (12/18/2025): $1.64 | Market Cap: $3.0 MilSector: Health Care | Industry: Life Sciences Tools & Services

Venus Concept (VERO)

Market Price (12/18/2025): $1.64Market Cap: $3.0 MilSector: Health CareIndustry: Life Sciences Tools & Services

Valuation, Metrics & Events

VERO Stock

Why The Stock Moved

Qualitative Assessment

Stock Movement Drivers

Fundamental Drivers

Market Drivers

Fundamental Drivers

Market Drivers

Fundamental Drivers

Market Drivers

Fundamental Drivers

Market Drivers

Return vs. Risk

Price Returns Compared

How Low Can It Go

In The Past

Preserve Wealth

Asset Allocation

About Venus Concept (VERO)

Global Medical Aesthetics Market

U.S. Medical Aesthetics Market

Global Hair Restoration Market

U.S. Hair Restoration Market

Global Skin Resurfacing Market

Global Body Contouring Market

U.S. Body Contouring Market

Global Cellulite Reduction Market

U.S. Cellulite Reduction Market

Global Acne Treatment Market

North America Acne Treatment Market

Share Issuance

Inbound Investments

Outbound Investments

Interactive Breakdown

Better Bets than Venus Concept (VERO)

Latest Trefis Analyses

Trade Ideas

Recent Active Movers

1 Day Top Gainers

1 Day Top Losers

1 Week Top Gainers

1 Week Top Losers

1 Month Top Gainers

1 Month Top Losers

Recent Active Movers

1 Day Top Gainers

1 Day Top Losers

1 Week Top Gainers

1 Week Top Losers

More From Trefis

Research & Analysis

Invest in Strategies

Wealth Management

Peer Comparisons for Venus Concept

Financials

Growth & Margins

Valuation

Returns

Comparison Analyses

FDIC Bank Data

Bank Capital

Bank Deposits

Bank Assets

Bank Loans

Financials

Segment Financials

Price Behavior

Based On 1-Year Data

Based On 5-Year Data

Based On 10-Year Data

Short Interest

Returns Analyses

Earnings Returns History

SEC Filings

Insider Activity

Market Price (12/18/2025): $1.64 | Market Cap: $3.0 Mil
Sector: Health Care | Industry: Life Sciences Tools & Services

Market Price (12/18/2025): $1.64
Market Cap: $3.0 Mil
Sector: Health Care
Industry: Life Sciences Tools & Services